Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee
Program: Abstract Session

Rheumatoid Arthritis (RA)
General Topic: Clinical Science

27M34: Abstracts: Rheumatoid Arthritis – Treatment I: Preventative and Novel Treatments (1674–1679)

Monday, October 27, 2025
1:00 PM - 2:30 PM Central Time
Location: S105
CE: 0.00

Non-CME In Person On Demand

    Abstract Moderator(s)

  • RB

    Rebecca Blank, MD, PhD

    NYU
    New York, New York, United States

    Disclosure information not submitted.

  • CL

    Carlos Lozada, MD

    University of Miami Miller School of Medicine
    Weston, Florida, United States

    Disclosure information not submitted.

Please note: This session is not eligible for CME Credits.

Presentations:

  • 1:00 PM - 1:15 PM Central Time
    A Phase 2, Randomized, Placebo-controlled Trial of Hydroxychloroquine in Individuals At-risk for Future Rheumatoid Arthritis

    Presenting Author: Kevin Deane, MD, PhD – University of Colorado Denver Anschutz Medical Campus

  • 1:15 PM - 1:30 PM Central Time
    Neuroimmune modulation in patients with active rheumatoid arthritis with an inadequate response to TNF inhibitors (TNFi)

    Presenting Author: Guillermo Valenzuela, MD, FACR – Guillermo Valenzuela MD PA/ IRIS Rheumatology

  • 1:30 PM - 1:45 PM Central Time
    Long-Term Safety and Efficacy of Upadacitinib or Adalimumab in Patients With Rheumatoid Arthritis: 7-Year Data From the SELECT-COMPARE Study

    Presenting Author: Roy Fleischmann, MD – Metroplex Clinical Research Center

  • 1:45 PM - 2:00 PM Central Time
    First line anti-TNF therapy in early rheumatoid arthritis is associated with a lower frequency of difficult-to-treat disease at five years and better long-term outcomes compared with usual care

    Presenting Author: Task Toyoda, MBBS, MRCP (he/him/his) – University of Leeds

  • 2:00 PM - 2:15 PM Central Time
    Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept Long Term Outcomes (ALTO) Study

    Presenting Author: Andrew Cope, MD, PhD – King's College London

  • 2:15 PM - 2:30 PM Central Time
    Does First-Line b- or tsDMARDs Choice Influence Progression to Difficult-to-Treat Rhumatoid arthritis? Insights from our longitudinal RA UCLouvain Brussels cohort

    Presenting Author: Francesco Natalucci, MD, PhD – UCLouvain University